Delivery Order SPE2DB20D2104-SPE2DB24FS39V
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,511.18, is for the delivery of GLATIRAMER 40 MG/ML SYRINGEML, a specialty pharmaceutical product. The contract has an ultimate completion date of March 11, 2025 and is a Firm Fixed Price Delivery Order. The contract was not designated with a set-aside requirement, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,911.09 firm fixed-price delivery order is for the supply of GLATIRAMER 40 MG/ML SYRINGEML, a medication, with an ultimate completion date of March 27, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of GLATIRAMER 40 MG/ML SYRINGE medications. The contract has a completion date of February 16, 2024 and a potential value of $2,832.12. The award does not have a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor and is responsible for delivering the pharmaceutical products to DLA Troop...
- This federal contract award was granted to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The $18,030.03 firm fixed price delivery order is for the supply of GLATIRAMER 40 MG/ML SYRINGEML, a specialty pharmaceutical product, to support the requirements of the Defense Logistics Agency (DLA) Troop Support Medical. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA valued at up to $999,999,999.00 through...
- This federal contract award is for the delivery of glatiramer 40 mg/ml syringes, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, under a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,834.96 firm-fixed-price delivery order is for the supply of 4565006756 GLATIRAMER 40 MG/ML SYRINGEML, a medical product, with a completion date of June 27, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4564082002 - GLATIRAMER 40 MG/ML SYRINGEML. The award, valued at $2,937.92, has a period of performance through March 27, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical distribution company. The award is for the supply of GLATIRAMER 40 MG/ML SYRINGEML, a specialty pharmaceutical product, with a potential value of $2,832.12 and a completion date of February 9, 2024. Amerisourcebergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical products and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,832.12 Firm Fixed Price delivery order is for the supply of 4560559530 units of glatiramer 40 mg/ml syringes, with a performance period ending on April 12, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of glatiramer 40 mg/mL syringes, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $4,888.11 and a period of performance through April 23, 2024. It is a firm-fixed price delivery order contract, with no set-aside designation. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC)...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FS39VDelivery Order
This federal contract award is for the delivery of GLATIRAMER 40 MG/ML SYRINGEML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor. The contract is a Delivery Order with a Firm Fixed Price of $10,837.26 and a period of performance through February 6, 2024. This award does not have a set-aside designation, indicating it was competed on the open market. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.8k | 2/5/24 |